# Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )

> **NCT06939036** · PHASE1,PHASE2 · TERMINATED · sponsor: **Ariceum Therapeutics GmbH** · enrollment: 2 (actual)

## Conditions studied

- Small Cell Lung Cancer Extensive Stage
- Merkel Cell Carcinoma

## Interventions

- **DRUG:** 225Ac-SSO110 + SoC
- **DRUG:** Atezolizumab
- **DRUG:** Durvalumab
- **DRUG:** Avelumab
- **DRUG:** Pembrolizumab
- **DRUG:** Retifanlimab

## Key facts

- **NCT ID:** NCT06939036
- **Lead sponsor:** Ariceum Therapeutics GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-07-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study terminated due to strategic business decisions.
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06939036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06939036, "Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06939036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*